A New Line Of Sight
Into Targeted Cancer Therapies

We understand the importance of collaboration in our industry and work closely with partners to help achieve our mission of developing innovative, targeted alpha-particle theranostics


If you are interested in partnering with us, we want to hear from you.


Eichrom Technologies LLC.

Eichrom Technologies and subsidiaries are world leaders in radiochemistry and radiometal separations technologies, as well as in custom radiation protection solutions under it’s subsidiary Nuclear Power Outfitters. Founded in 1990, Eichrom has been at the forefront of radiometal chromatographic separations product development and commercialization in the areas of radiochemistry, radiopharmaceuticals, nuclear medicine, and geochemistry.

Pepscan Therapeutics B.V.

Pepscan is an all-in-one partner in peptides, building on 25 years of experience in advancing and applying peptide expertise to facilitate customers in the development and production of peptides. At its end-to-end facility in Lelystad, the Netherlands, Pepscan offers a range of patented technologies, phage display capabilities, a lead-optimization array platform, and production facilities for R&D- to GMP-grade peptides, including libraries and neoantigen vaccines. Among its patents is the CLIPS™ technology, which locks peptides into active conformations.

Pepscan has a proven track record in the field of radiopharmaceuticals and synthesized precursors for radiolabeled peptides suitable for a wider range of applications. Its unique CLIPS™ phage display platform enables the discovery of highly constrained de novo peptides with enhanced affinities, selectivities and proteolytic stabilities. Next to the peptides emerging from the discovery platform, Pepscan has successfully produced radiopharmaceutical peptides as developed by customers themselves.


SpectronRx is a Contract Development Manufacturing Organization (CDMO) based in Indianapolis, Indiana focused on producing diagnostic and therapeutic solutions for the Nuclear Medicine and Molecular industry (research, clinical and commercial radiopharmaceutical supply), with special focus on monoclonal and small molecule radiopharmaceutical labeling.

Special Acknowledgement

National Isotope Development Center of the U.S. Department of Energy Isotope Program

Viewpoint would like to acknowledge the National Isotope Development Center (NIDC) and the DOE U.S. Department of Energy Isotope Program (DOE IP), which funds the NIDC, as the source of Th-228 for Viewpoint. NIDC serves as an interface with the user community and manages the coordination of isotope production across the program facilities at Argonne, Brookhaven, Idaho, Los Alamos, Oak Ridge, and Pacific Northwest National Laboratories. These facilities produce stable and radioactive isotopes in short supply using reactors, accelerators, and other methods.

The DOE IP supports the production and the development of production techniques of radioactive and stable isotopes that are in short supply for research and applications. Isotopes are high-priority commodities of strategic importance for the nation and are essential for energy, medical, national security applications and for basic research; a goal of the program is to make critical isotopes more readily available to meet domestic U.S. needs.

The program coordinates and supports isotope production at numerous universities and national laboratories throughout the nation to promote a reliable supply of domestic isotopes. The NIDC coordinates isotope production across these facilities and manages the business operations of the sale and distribution of isotopes.